Frank Hazevoets
Chief Executive Officer chez DMS IMAGING
Profil
Frank Hazevoets is currently the CEO, Managing Director, CFO & Executive Director at DMS Imaging SA since 2020.
Previously, he worked as the Director-Strategy & Internal Growth at InBev SA from 2001 to 2006.
From 2006 to 2012, he served as the Chief Financial Officer & Secretary at TiGenix NV.
He also held the position of Principal at Smeets Securities BV and Puilaetco.
Additionally, he worked as the CFO & Head-Corporate Development at PROMETHERA Biosciences SA from 2014 to 2018.
Mr. Hazevoets completed his undergraduate and graduate degrees at Université Catholique de Louvain.
Postes actifs de Frank Hazevoets
| Sociétés | Poste | Début |
|---|---|---|
| DMS IMAGING | Chief Executive Officer | 13/10/2020 |
Anciens postes connus de Frank Hazevoets
| Sociétés | Poste | Fin |
|---|---|---|
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Director of Finance/CFO | 05/10/2018 |
| TIGENIX NV | Director of Finance/CFO | 01/01/2012 |
| InBev SA | Corporate Officer/Principal | 01/01/2006 |
| Smeets Securities BV | Corporate Officer/Principal | - |
| Puilaetco | Corporate Officer/Principal | - |
Formation de Frank Hazevoets
| Université Catholique de Louvain | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DMS IMAGING | Health Technology |
| Entreprise privées | 5 |
|---|---|
| InBev SA | Consumer Non-Durables |
TiGenix NV
 TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
| Smeets Securities BV | |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
| Puilaetco | Finance |
